標(biāo)題: Titlebook: Emerging Therapeutic Targets in Ovarian Cancer; Stan Kaye,Robert Brown,Martin Gore Book 2011 Springer Science+Business Media, LLC 2011 [打印本頁(yè)] 作者: Hallucination 時(shí)間: 2025-3-21 19:37
書目名稱Emerging Therapeutic Targets in Ovarian Cancer影響因子(影響力)
書目名稱Emerging Therapeutic Targets in Ovarian Cancer影響因子(影響力)學(xué)科排名
書目名稱Emerging Therapeutic Targets in Ovarian Cancer網(wǎng)絡(luò)公開度
書目名稱Emerging Therapeutic Targets in Ovarian Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Emerging Therapeutic Targets in Ovarian Cancer被引頻次
書目名稱Emerging Therapeutic Targets in Ovarian Cancer被引頻次學(xué)科排名
書目名稱Emerging Therapeutic Targets in Ovarian Cancer年度引用
書目名稱Emerging Therapeutic Targets in Ovarian Cancer年度引用學(xué)科排名
書目名稱Emerging Therapeutic Targets in Ovarian Cancer讀者反饋
書目名稱Emerging Therapeutic Targets in Ovarian Cancer讀者反饋學(xué)科排名
作者: 詞匯記憶方法 時(shí)間: 2025-3-21 23:18 作者: 官僚統(tǒng)治 時(shí)間: 2025-3-22 00:42
Epigenetic Therapies,d the achievement of a clear therapeutic index. In addition, the development of robust predictive biomarkers linked to an understanding of the underlying biology will be key to improved epigenetic therapy approaches. Defining the epigenetic alongside the genetic landscape of individual ovarian cance作者: 不能和解 時(shí)間: 2025-3-22 06:07 作者: 粗鄙的人 時(shí)間: 2025-3-22 10:09 作者: FLUSH 時(shí)間: 2025-3-22 15:43
French Nuclear Command and Control,e in ovarian cancer and summarise the current progress in developing clinically applicable inhibitors of AKT pathway components for potential use in the ovarian cancer setting either alone or in combination with conventional cytotoxic agents such as the platinum drugs.作者: FLUSH 時(shí)間: 2025-3-22 20:09 作者: Geyser 時(shí)間: 2025-3-22 21:52
Specific Measurements, Units, and Termss have been implicated in T-cell suppression mediated by a number of cell surface molecules such as B7-H1 or enzymes such as arginase. Inflammation may be important in mediating suppression or defective response to treatment. Novel immune therapies have endeavoured to address immune suppression alon作者: 暗諷 時(shí)間: 2025-3-23 02:44
https://doi.org/10.1007/978-90-481-3411-3appears to reverse platinum-resistance, in part, by upregulation of caspase-3-mediated apoptosis. Src is an attractive target in ovarian cancers, and current trials using various Src inhibitors are underway.作者: 六邊形 時(shí)間: 2025-3-23 05:48 作者: Cuisine 時(shí)間: 2025-3-23 10:34 作者: Agnosia 時(shí)間: 2025-3-23 14:54
The Nuclear Weapons Proliferation Issue about ovarian cancer stem cells. We then explore the potential for therapeutic targeting of these cells, and what the future holds for implementation of such approaches toward improving survival of women with ovarian cancer.作者: 肥料 時(shí)間: 2025-3-23 18:17
Nuclear Facilities, Decommissioning of,and adverse effects. This review will focus on the current understanding of how the biology of the microtubule and control of cell cycle may explain taxane resistance and inform the development of new therapeutics and treatment strategies.作者: 發(fā)芽 時(shí)間: 2025-3-24 00:43
Inhibition of the Src Oncogene: Therapeutic Potential in Ovarian Carcinoma,appears to reverse platinum-resistance, in part, by upregulation of caspase-3-mediated apoptosis. Src is an attractive target in ovarian cancers, and current trials using various Src inhibitors are underway.作者: jaundiced 時(shí)間: 2025-3-24 05:15
Tumour-Specific Synthetic Lethality: Targeting , Dysfunction in Ovarian Cancer,ularly in high-grade serous ovarian cancers has now led to the testing of these novel therapeutics in broader groups of women with this disease. The stage is now set for this tumour-specific synthetic lethal approach to have a positive impact on women in the gynae-oncology clinic.作者: 臭名昭著 時(shí)間: 2025-3-24 08:50 作者: resilience 時(shí)間: 2025-3-24 13:56
Ovarian Cancer Progenitor/Stem Cells: Therapeutic Potential, about ovarian cancer stem cells. We then explore the potential for therapeutic targeting of these cells, and what the future holds for implementation of such approaches toward improving survival of women with ovarian cancer.作者: 拋物線 時(shí)間: 2025-3-24 17:51 作者: 形容詞 時(shí)間: 2025-3-24 21:15
https://doi.org/10.1007/978-94-011-2826-1y advances in both surgical and chemotherapeutic strategies. In this introductory chapter, we summarise the existing treatments for epithelial ovarian cancer, introduce recent advances, and highlight unmet needs in the treatment of epithelial ovarian cancer.作者: deactivate 時(shí)間: 2025-3-25 00:54 作者: legacy 時(shí)間: 2025-3-25 05:43 作者: 大洪水 時(shí)間: 2025-3-25 09:28
Effects of Radiation Exposures,dies, folate-conjugated drug carriers and imaging agents. The preclinical and emerging clinical data demonstrate that the α-FR is an important therapeutic target in cancer with particular relevance in non-mucinous ovarian carcinoma.作者: Scleroderma 時(shí)間: 2025-3-25 12:17
Systemic Therapy for Ovarian Cancer, Current Treatment, Recent Advances, and Unmet Needs,y advances in both surgical and chemotherapeutic strategies. In this introductory chapter, we summarise the existing treatments for epithelial ovarian cancer, introduce recent advances, and highlight unmet needs in the treatment of epithelial ovarian cancer.作者: LIMN 時(shí)間: 2025-3-25 18:50
Novel Anti-angiogenic Therapies in Ovarian Cancer, focuses on the emergent data of new anti-angiogenic therapies in advanced ovarian cancer. We describe the developments to date, ongoing pivotal studies and critically appraise the role of novel anti-angiogenics in the treatment of ovarian cancer.作者: ORE 時(shí)間: 2025-3-25 23:35 作者: MEET 時(shí)間: 2025-3-26 01:08 作者: 節(jié)約 時(shí)間: 2025-3-26 05:09 作者: Intrepid 時(shí)間: 2025-3-26 11:49 作者: 遣返回國(guó) 時(shí)間: 2025-3-26 14:01 作者: Eosinophils 時(shí)間: 2025-3-26 18:13
Targeting the AKT Pathway in Ovarian Cancer,abolism and survival. In ovarian cancer, alterations have been observed in both the catalytic and regulatory subunits of the PI3K enzyme, in the opposing phosphatase PTEN and in each of the three isoforms of AKT itself. The net effect is a frequent hyperactivation of the pathway which has been linke作者: 表示向前 時(shí)間: 2025-3-26 21:32 作者: 使入迷 時(shí)間: 2025-3-27 04:39
Tumour-Specific Synthetic Lethality: Targeting , Dysfunction in Ovarian Cancer,utation carriers and 10–20% for . carriers The analysis of . and . function in DNA repair is leading to new approaches to antitumour therapy for such patients, including the use of poly(ADP)-ribose polymerase (PARP) inhibitors. Such novel agents are selectively lethal to cells lacking functional . o作者: 脫離 時(shí)間: 2025-3-27 06:20
Targeting Inflammatory Pathways in Epithelial Ovarian Cancer,irst-line therapy, attempts at improving survival rates in this setting by combining standard treatment with other cytotoxic agents have only had limited success. In platinum-resistant/refractory disease, single agents have modest activity with an average response rate of 20%. As it appears that a t作者: Mobile 時(shí)間: 2025-3-27 12:14
Epithelial-to-Mesenchymal Transition and Cellular Membrane Receptors in Ovarian Cancer: Moving Forwalignant disease have had varying levels of success in the treatment of patients with ovarian cancer. This chapter will discuss in depth the following cell membrane receptors and proteins: integrins, the EGFR/HER family of receptors, IGF receptors, c-Met, and will mention cadherins and the transform作者: 慎重 時(shí)間: 2025-3-27 14:14 作者: 高調(diào) 時(shí)間: 2025-3-27 18:23
Ovarian Cancer Immunology and Immunotherapy,in its management, new therapies are required in order to improve disease control and survival. The immune system protects us from developing cancer but once ovarian cancer is established, it employs elaborate pathways to circumvent the immune system. Immune suppression in the form of defective anti作者: cumber 時(shí)間: 2025-3-27 23:47 作者: 纖細(xì) 時(shí)間: 2025-3-28 02:28
,Potential for α-Folate Receptor-Targeted Treatment for Ovarian Cancer,late drugs are largely transported into tumours and normal tissues via the high capacity reduced-folate carrier (RFC). A new generation of antifolates and folate–drug conjugates have been discovered that are preferentially transported via FRs and, because of highly restricted expression in normal ti作者: 掙扎 時(shí)間: 2025-3-28 06:33 作者: HARD 時(shí)間: 2025-3-28 13:45
https://doi.org/10.1007/978-94-011-2826-1advanced disease with little prospect of cure. The optimal management of epithelial ovarian cancer involves a multidisciplinary approach incorporating surgical staging, cytoreduction, and platinum-based chemotherapy in appropriate patients. There has been little overall change in the incidence and m作者: itinerary 時(shí)間: 2025-3-28 16:18 作者: CAMEO 時(shí)間: 2025-3-28 21:28
Maheshwar Sharon,Madhuri Sharonc compounds led by the confirmation of bevacizumab as a key component of front-line therapy in advanced colorectal cancer in 2004. Ovarian cancer is one of only a few solid tumours that responds to single-agent anti-VEGF therapy. VEGF inhibitors are also active when administered in combination with 作者: Gingivitis 時(shí)間: 2025-3-28 23:15
French Nuclear Command and Control,abolism and survival. In ovarian cancer, alterations have been observed in both the catalytic and regulatory subunits of the PI3K enzyme, in the opposing phosphatase PTEN and in each of the three isoforms of AKT itself. The net effect is a frequent hyperactivation of the pathway which has been linke作者: 山崩 時(shí)間: 2025-3-29 04:28
https://doi.org/10.1007/978-90-481-3411-3nesis with indirect effects exerted through VEGF. Additional potent pro-angiogenic cytokines such as IL-6 and IL-8 act via Src as well. Src also directly affects vascular permeability by impacting endothelial cadherin function, thereby inducing vascular leakage of tumor and interstitial fluid. Furth作者: 引起痛苦 時(shí)間: 2025-3-29 08:26
Nuclear Data for Science and Technologyutation carriers and 10–20% for . carriers The analysis of . and . function in DNA repair is leading to new approaches to antitumour therapy for such patients, including the use of poly(ADP)-ribose polymerase (PARP) inhibitors. Such novel agents are selectively lethal to cells lacking functional . o作者: 包裹 時(shí)間: 2025-3-29 13:41 作者: needle 時(shí)間: 2025-3-29 17:16
https://doi.org/10.1007/978-3-642-87663-9alignant disease have had varying levels of success in the treatment of patients with ovarian cancer. This chapter will discuss in depth the following cell membrane receptors and proteins: integrins, the EGFR/HER family of receptors, IGF receptors, c-Met, and will mention cadherins and the transform作者: 領(lǐng)巾 時(shí)間: 2025-3-29 20:40
Specific Measurements, Units and Terms. Such epigenetic mechanisms include DNA methylation, post-translational modifications of histones and non-coding RNAs. All types of ovarian cancer show wide-spread aberrant epigenetic changes, leading to changes in expression of genes involved in all the hallmarks of cancer, as well as genes involv作者: RADE 時(shí)間: 2025-3-30 02:23 作者: 同音 時(shí)間: 2025-3-30 07:05
The Nuclear Weapons Proliferation Issueruct the heterogeneity of the original tumor in immunocompromised mice through asymmetric cell division. As satisfying as the concept of an ovarian cancer stem cell is to explain the origins of ovarian cancer, can this concept be applied universally to explain the diversity in the histologic types o作者: 加劇 時(shí)間: 2025-3-30 10:50 作者: tenosynovitis 時(shí)間: 2025-3-30 15:30 作者: rectocele 時(shí)間: 2025-3-30 20:03
